Assetmark Inc. grew its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 88.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,369 shares of the company’s stock after purchasing an additional 5,339 shares during […]
Jacob Asset Management of New York LLC raised its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 1,017.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,850 shares of the company’s stock after buying an additional 4,416 shares during the quarter. […]
Inspire Advisors LLC reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 50.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,115 shares of the company’s stock after selling 6,342 shares during the period. Inspire […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective cut by Citigroup from $70.00 to $67.00 in a research note published on Friday, Benzinga reports. They currently have a buy rating on the stock. Other analysts have also recently issued reports about the company. Bank of America upgraded Apellis Pharmaceuticals from a neutral rating […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CEO Cedric Francois sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the sale, the chief executive officer now owns […]